Dr. Reddy’s moves first in Canada’s generic semaglutide market. Can access improve?
GLP-1 demand is booming, but access remains uneven. Dr. Reddy’s Canada launch tests whether generics can change semaglutide economics.
Pharma & Biotech
Pharma & Biotech
What sets Hanmi’s GLP-1 strategy apart as efpeglenatide heads into Latin America
Hanmi taps Sanfer to launch GLP-1 drug efpeglenatide in Mexico. Find out what this deal reveals about Latin America’s obesity drug market strategy.